Delivery Order SPE2DB24D8003-SPE2DB25FJTTS

Award Date 2/4/25
Potential Completion Date 2/5/25
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, identified as SPE2DB24D8003 and SPE2DB25FJTJF, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a total ceiling value of $1,491.37. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is November 25, 2024. Dakota Drug, Inc. is a key supplier of...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKYYT, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business based in Anoka, Minnesota. The $2,994.06 firm fixed-price delivery order is for the provision of ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program,...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract has a Firm Fixed Price pricing type, a ceiling value of $1,665.49, and a period of performance through February 19, 2025. This Delivery Order is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT...
This federal contract award, SPE2DB24D8003|SPE2DB25FJTPG, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $3,266.30 firm fixed-price delivery order is for the provision of ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The award is not associated with a set-aside program and has an ultimate completion date of January 6, 2025. Dakota Drug, Inc. is the prime contractor and has a significant single-award...
This federal contract award, valued at $1,705.26, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is a delivery order awarded under DLA's ECAT Generation V Program, a large Indefinite Delivery Contract (IDC) with a ceiling value of $999,999,999.00 that enables Dakota Drug, Inc. to provide a range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations....
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract has a ceiling value of $3,707.66 and a period of performance through February 24, 2025. The contract is for the delivery of pharmaceutical products, including ZEPBOUND 15 MG/0.5 ML PEN 0.5ML, to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKZBN, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of pharmaceutical products, medical supplies, and healthcare equipment, including items such as Dupixent 300 mg/2 ml pens, to support U.S. Armed Forces medical operations. The contract has a ceiling value of $6,318.05 and a period of performance extending through January 21,...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, identified as SPE2DB24D8001 and SPE2DB25FKZED, is a Delivery Order with a Firm Fixed Price pricing type. The contract has a ceiling value of $2,077.19 and an ultimate completion date of February 11, 2025. The contract is for the delivery of pharmaceutical products, medical supplies, and healthcare equipment, primarily to support U.S....
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBQXG, was issued by the Defense Logistics Agency (DLA) Medical Supply Chain division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $2,159.86 firm fixed-price delivery order is for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML, a pharmaceutical product, with a performance period ending on May 9, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, contract number...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $4,904.78, is for the delivery of Actemra Actpen 162 mg/0.9 ml, a pharmaceutical product, to support U.S. Armed Forces medical operations. The contract is a Firm Fixed Price Delivery Order with a performance period ending on May 22, 2024. Dakota Drug, Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the...
  • SPE2DB24D8003
    Indefinite Delivery Contract
  • SPE2DB24D8003-SPE2DB25FJTTS
    Delivery Order

This federal contract award, identified as SPE2DB24D8003|SPE2DB25FJTTS, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a ceiling value of $1,848.11 and a performance period extending through February 5, 2025. This contract is not set aside and is a Firm Fixed Price Delivery Order.

Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense, primarily through the DLA Troop Support Medical division. The company holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00, which allows it to provide a comprehensive range of medical items to support U.S. Armed Forces medical operations.

Generated 5/21/25, 9:44 AM